Next Article in Journal
The Side Effects and Adverse Clinical Cases Reported after COVID-19 Immunization
Previous Article in Journal
Efficacy and Immunogenicity of Recombinant Pichinde Virus-Vectored Turkey Arthritis Reovirus Subunit Vaccine
Article

Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine

1
Department of Social and Environmental Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan
2
Cellspect Co., Ltd., 2-4-23 Kitaiioka, Morioka 020-0857, Japan
3
Department of Preventive Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan
4
Clinical Epidemiology Research Center, Medical Co., LTA(SOUSEIKAI), Higashi-ku, Fukuoka 813-0017, Japan
*
Authors to whom correspondence should be addressed.
Academic Editor: Luis Martinez-Sobrido
Vaccines 2022, 10(4), 487; https://doi.org/10.3390/vaccines10040487
Received: 21 February 2022 / Revised: 17 March 2022 / Accepted: 18 March 2022 / Published: 22 March 2022
The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has required rapid action to control its spread and vaccines are a fundamental solution to this pandemic. The development of rapid and reliable serological tests to monitor the antibody response to coronavirus disease vaccines is necessary for post-vaccination immune responses. Therefore, in this study, anti-SARS-CoV-2 antibody titers after the first and second doses were monitored using two different measurement systems, a highly sensitive analytical platform of chemiluminescent enzyme immunoassay (CLEIA) and an enzyme-linked immunosorbent assay (ELISA). Our study included 121 participants who received two doses of the BNT162b2 vaccine. Both methods show significant increase in anti-spike protein IgG antibody levels one week after the first vaccination, and then reached at a plateau at week five (week two after the second dose), with a 3.8 × 103-fold rise in CLEIA and a 22-fold rise in ELISA. CLEIA and ELISA showed a good correlation in the high titer range, >10 binding antibody unit (BAU)/mL. Both methods detected higher IgG antibody levels in females compared with male participants after the second vaccination, while CLEIA exhibits the sex difference after the first dose. Thus, our study showed better performance of CLEIA over ELISA in sensitivity, especially in the low concentration range, however ELISA was also useful in the high titer range (>10 BAU/mL) corresponding to the level seen several weeks after the first vaccination. View Full-Text
Keywords: antibody; COVID-19; SARS-CoV-2; immunoassay tests; vaccination antibody; COVID-19; SARS-CoV-2; immunoassay tests; vaccination
Show Figures

Figure 1

MDPI and ACS Style

Ashenagar, M.S.; Matsumoto, A.; Sakai, H.; Tokiya, M.; Hara, M.; Hirota, Y. Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine. Vaccines 2022, 10, 487. https://doi.org/10.3390/vaccines10040487

AMA Style

Ashenagar MS, Matsumoto A, Sakai H, Tokiya M, Hara M, Hirota Y. Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine. Vaccines. 2022; 10(4):487. https://doi.org/10.3390/vaccines10040487

Chicago/Turabian Style

Ashenagar, Mohammad S., Akiko Matsumoto, Hironori Sakai, Mikiko Tokiya, Megumi Hara, and Yoshio Hirota. 2022. "Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine" Vaccines 10, no. 4: 487. https://doi.org/10.3390/vaccines10040487

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop